Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of PANDA-VAC with Pembrolizumab in Advanced Squamous NSCLC and SCCHN
NCT04266730Phase 1Suspended
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- May 2027
- Primary completion
- Jun 2027
- Modality
- Peptides, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of panda-vac in squamous cell carcinoma of the lung (SCCL) and head and neck squamous cell carcinoma (HNSCC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Number of adverse events at 8 weeks. Planned start May 2027; status: suspended.
02
Drugs
panda-vac
03
Conditions
squamous cell carcinoma of the lung (SCCL)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04266730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04266730.